Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth shows Pristiq to reduce MDD symptoms

Wyeth shows Pristiq to reduce MDD symptoms

14th December 2007

Wyeth Pharmaceuticals has released new data from two phase III studies of its investigational serotonin-norepinephrine reuptake inhibitor, Pristiq (desvenlafaxine), in patients with major depressive disorder (MDD).

It was found that adult patients with MDD who received 50mg per day of Pristiq experienced a statistically significant reduction in symptoms of major depression compared to a placebo.

The two studies were evaluating the efficacy and safety of Pristiq 50mg and 100mg and will be presented this week.

Philip Ninan, vice-president of neuroscience at Wyeth, confirmed that the response rates of patients in the 50mg per day dose groups were similar to that of the rates seen in higher doses.

“We are also encouraged by the tolerability profile shown in the two studies presented at this meeting. Notably, subjects in the 50mg/day dose groups were not titrated from a lower dose when initiating therapy,” he added.

Wyeth has announced that it expects action to be taken by the US Food and Drug Administration on its Pristiq approval application early next year.

Earlier this month, Wyeth announced that it has been recognised for its pharmaceutical and scientific achievements at the third annual Scrip Awards ceremony, where it received honours for Best Overall Pipeline and Best New Drug.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.